1. DSpace at Nirma University
  2. 04. Institute of Pharmacy
  3. B. Pharm Project Reports
Please use this identifier to cite or link to this item: http://10.1.7.192:80/jspui/handle/123456789/9775
Full metadata record
DC FieldValueLanguage
dc.contributor.authorGandhi, Samkit S.-
dc.date.accessioned2021-02-12T06:17:21Z-
dc.date.available2021-02-12T06:17:21Z-
dc.date.issued2020-05-
dc.identifier.urihttp://10.1.7.192:80/jspui/handle/123456789/9775-
dc.descriptionGuided by Dr. Bhagwati Saxenaen_US
dc.description.abstractParkinson’s disease (PD) occurs mainly at an elderly age. It is the second most occurring neurodegenerative progressive disorder of movement. It is due to aggregation of α-synuclein (a protein normally involved in vesicle recycling) in the form of characteristic Lewy bodies. There are many therapeutic targets available for treatment of PD like α-7 nicotinic receptors, PPARγ and PGC-1α, misfolded α-synuclein and toll-like receptors, the transcription factor Nrf2, mixed lineage kinase(MLK)– c-jun n-terminal kinase (JNK) signaling pathway are the 5 target of therapeutic that has been discussed in this review article.en_US
dc.publisherInstitute of Pharmacy, Nirma University, A'baden_US
dc.relation.ispartofseriesPPR01019;-
dc.subjectPPR01019en_US
dc.subjectB. Pharm Project Reporten_US
dc.subjectPharmacologyen_US
dc.subjectParkinson’s diseasesen_US
dc.subjectPathogenesisen_US
dc.subjectTherapeutic targetsen_US
dc.subjectα-synucleinen_US
dc.subjectKinaseen_US
dc.subjectDopamineen_US
dc.subjectPPARγ,en_US
dc.titleNewer Therapeutic Targets for Parkinson Diseaseen_US
dc.typeProject Reporten_US
Appears in Collections:B. Pharm Project Reports

Files in This Item:
File Description SizeFormat 
PPR01019.pdfPPR010192.21 MBAdobe PDFThumbnail
View/Open
Show simple item record


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.